Oxford-AstraZeneca vaccine gets conditional nod for emergency use in India


New Delhi : Covishield, the COVID Vaccine prepared by Oxford university and AstraZeneca has been cleared by a government expert group for emergency use in India.

An expert panel at the Central Drug standard Control of India (CDSCO) has recommended a conditional approval to the vaccine. The vaccine is being produced by the Serum Institute of India in the country.

Earlier on Friday, Adar Punawalla, CEO of Serum Institute said “For the Government of India, Covishield will cost about USD 3 per dose, so USD 6 [Rs 440] per person, but for the private market, it will cost around Rs 700-800.”

According to reports, Serum Institute has already stockpiled over 50 million doses of the vaccine and is ready to scale up production to meet the demand.

Leave A Reply

Your email address will not be published.